Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Trial details
- Registry ID
- NCT02682511
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Ifetroban
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511 | Cumberland Pharmaceuticals | Phase 2 | Active not recruiting | 2026-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |